Mersana Therapeutics (MRSN) Tops Q4 EPS by 5c

Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $10.7 million versus the consensus estimate of $9.1 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• NextPlat Corp (NXPL) Reports Q2 Loss of $0.05
• Euroseas Ltd. (ESEA) Tops Q2 EPS by 61c